Brisou, G., Paillassa, J., Bernard, S., Tournilhac, O., Fornecker, L.-M., Maloisel, F., Gastaud, L., Durot, E., Tempescul, A., Braun, T., Ivanov, V., Cherel, B., Serrier, C., Delage, J., El Yamani, A., Delapierre, B., Lebras, L., Lestang, E., Villesuzanne, C., Agape, P., Escure, G., Fouillet, L., Nicol, C., Olivier, G., Levy, A., Le Bris, A.-S., Cassuto, O., Jacquemelle, L., Haioun, C. and Herbaux, C. (2025) “Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study”, Haematologica. Pavia, Italy, 110(10), pp. 2400-2412. doi: 10.3324/haematol.2024.287141.